Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ethicon Endo-Surgery Picks Up Obesity Neurostim Patents From Cyberonics

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson subsidiary Ethicon Endo-Surgery expanded its obesity treatment portfolio Dec. 18, gaining exclusive rights to neurostimulation patents from Cyberonics

You may also be interested in...

Financings In Brief

Inverness raises funds for more acquisitions: Diagnostics firm will gross about $728 million from the sale of 11.8 million shares of its common stock at $61.49 each, expected to close Nov. 20, the firm announces Nov. 15. Proceeds are tabbed for working capital and "potential acquisitions or other investments, if and when suitable opportunities arise," the company says. Inverness Medical Innovations, which has inked more than a dozen acquisition deals so far this year, recently indicated that it plans to keep up the pace, with the goal of growing annual revenues to $3 billion by 2012 (1"The Gray Sheet" Nov. 5, 2007, p. 16). The Waltham, Mass.-based company notes that it also may use a portion of the anticipated proceeds from the stock offering to complete its pending $37 million acquisition of Australian diagnostics firm Panbio, which was announced Oct. 8 (2"The Gray Sheet" Oct. 15, 2007, In Brief). Underwriters for the stock offering include UBS Investment Bank, Jefferies & Company, Merrill Lynch, Leerink Swann, and Stifel, Nicolaus & Company. Inverness stock trades on the Amex exchange under the symbol "IMA.

Underpenetrated U.S. Gastric Banding Market Has Room For Two

With Johnson & Johnson expected to launch its Realize adjustable gastric band in the United States by the end of the year, what physicians and analysts consider a highly underpenetrated market will finally have some competition

Stakeholders Gather To Discuss Pandemic Response And Next Steps

As Europe’s health emergency body HERA approaches its first anniversary, an unprecedented range of stakeholders including industry bodies will be meeting in December to discuss HERA’s achievements, while a separate event will showcase the next generation of vaccines for COVID-19 and other infections.

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts